
More than 30% of patients with resectable colorectal cancer (CRC) have disease recurrence after surgery. Therefore, adjuvant chemotherapy (ACT) is recommended for those with stage III or stage II disease and high-risk clinicopathological features. However, this approach to patient selection is suboptimal, resulting in the overtreatment of many and the undertreatment of others. New data from the observational GALAXY cohort of the ongoing CIRCULATE-Japan study support the potential of minimal residual disease (MRD) to guide decision-making in this setting.
Like
Save
Share